AstraZeneca And Daiichi Reach Key Milestone In Breast Cancer ADC Trial, Paving Way To Challenge Gilead
Read More: pharmtales.com/dato-dxd-beats…
#pharmanews #pharmaupdates #Pharmtales #AntibodyDrugConjugates #AstraZeneca #breastcancer #DatopotamabDeruxtecan #GileadSciences
$AZN AstraZeneca lost £10bn after drug #datopotamabderuxtecan for non-small cell lung cancer effective, but disappointed w/safety issues. Corvus's $CRVS #Mupadolimab in Phase 1/1b trial w/ Angel for NSCLC and HNSCC as monotherapy/combo with #Keytruda .
theguardian.com/business/2023/…
#ASCO21
#BEGONIA Arm 7
TPS1105
#durvalumab + #DatopotamabDeruxtecan in 1⃣L metastatic #TNBC
Presented by #PeterSchmid
meetinglibrary.asco.org/record/201174/…
OncoAlert #bcsm
Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients - Piotr Wysocki
oncodaily.com/56332.html
#oncodaily #oncology #cancer #breastcancer #clinicaltrial #datopotamabderuxtecan #TROP2 …
AstraZeneca encouraged by positive results of TROPION-Breast01 Phase III trial
'Plans for global regulatory submissions underway'
Read More: tinyurl.com/2adwqep2
#AZN #RNS #Stocks #AstraZeneca #DaiichiSankyo #DatopotamabDeruxtecan #TROPIONBreast01
AstraZeneca encouraged by positive results of TROPION-Breast01 Phase III trial
'Plans for global regulatory submissions underway'
Read More: tinyurl.com/2adwqep2
#AZN #RNS #Stocks #AstraZeneca #DaiichiSankyo #DatopotamabDeruxtecan #TROPIONBreast01
#DatopotamabDeruxtecan Demonstrates Significant Progression-Free Survival Benefit in HR-Positive, HER2-Low or Negative #BreastCancer : TROPION-Breast01 Phase 3 Trial Results
ipharmacenter.com/post/european-…
#pharma #pharma ceutical #ESMO23 #ESMO2023 #ESMODailyReporter #news #BREAKING #media
#抗TROP2抗体薬物複合体 #DatopotamabDeruxtecan （ #DatoDXd ）が進行非扁平上皮非小細胞 #肺がん と、ホルモン受容体陽性HER2陰性の進行 #乳がん の2次/3次治療を対象とした申請が欧州で受理されました。
medical.nikkeibp.co.jp/leaf/all/cance…
#抗TROP2抗体薬物複合体 #DatopotamabDeruxtecan （Dato-DXd）が、ホルモン受容体陽性HER2陰性の手術不能または転移を有する #乳がん の2次/3次治療を対象に日本でも申請されました。早期の承認を期待します。
medical.nikkeibp.co.jp/leaf/all/cance…
抗TROP2抗体薬物複合体datopotamab deruxtecan（Dato-DXd、 DS-1062）が、転移を有するトリプルネガティブ乳がんに良好な抗腫瘍効果を示すことが報告されました。
＃乳がん #トリプルネガティブ #datopotamabderuxtecan #DatoDXd #SABCS21
medical.nikkeibp.co.jp/leaf/all/cance…
General session 1 at #SABCS21 : encouraging but preliminary data from phase I #TROPIOPanTumor01 trial with a new anti- #TROP2 #ADC #DatopotamabDeruxtecan in heavily pretreated patients with metastatic #TripleNegative #BreastCancer
OncoAlert #bcsm Dana-Farber Dana-FarberNews
#news - #Datopotamabderuxtecan demonstrated durable efficacy in heavily pretreated HR+/HER2-low or negative #breastcancer .
ipharmacenter.com/post/san-anton…
#SABCS 22 #SABCS 2022 #SABCS #pharma #pharma ceutical #healthcare #globalhealth #media #conferences #oncology #BreastCancerAwareness
#トリプルネガティブ乳がん の1次治療として、 #抗TROP2抗体薬物複合体 #datopotamabderuxtecan （Dato-DXd、 DS-1062）と #デュルバルマブ の併用が有効な可能性が報告されました。
#ESMOBreast2022
medical.nikkeibp.co.jp/leaf/all/cance…
CDSCO Panel gives nod Clinical Trial for this Anticancer Drug
#Anticancerdrug #CDSCOpanel #ClinicalTrial #Datopotamabderuxtecan #SEC #SubjectExpertCommittee
thehealthmaster.com/2023/01/01/cds…
#DaiichiSankyo reported that #TROPIONBreast02 Phase 3 Trial of #DatopotamabDeruxtecan Initiated in Patients with Previously Untreated #Metastatic #TripleNegative #BreastCancer 1stoncology.com/blog/tropion-b…
#AstraZeneca stock value falls by after cancer drug trial results
The pharmaceutical company shares closed down 8% after it published the first results from its third phase trial for #datopotamabderuxtecan .
#StockMarket
VIDEO: #DatopotamabDeruxtecan appears 'quite active' in pretreated #BreastCancer subset
Ian E. Krop, MD, Dana-Farber
ow.ly/8OvK50HiOJs
Healio
#IndustriaFarmacéutica : Novedades para datopotamab deruxtecán en pacientes con cáncer de pulmón no microcítico AstraZeneca España Daiichi Sankyo España 💊 #datopotamabderuxtecan #CPNM elmedicointeractivo.com/novedades-para…